CONSENSYS
17.11.2021 16:17:07 CET | Business Wire | Press release
Today, ConsenSys announced the close of a $200 million USD financing round, bringing its valuation to $3.2 billion USD. New investors Marshall Wace, Third Point, ParaFi Capital, and Think Investments contributed to the round alongside new partners that include Dragonfly Capital, Electric Capital, Spartan Group, DeFiance Capital, Animoca Brands, Coinbase Ventures, and HSBC. Sullivan & Cromwell LLP acted as ConsenSys’ legal advisor in this transaction.
ConsenSys’ mission is to unlock the collaborative power of communities by making Web3 universally easy to use, access, and build on. MetaMask is the primary way a global user base of approximately 21 million monthly active users — a 38x increase from 2020 — interacts with a universe of approximately 3,700 unique Web3 applications. Web3 allows creators to capture the true value of their work and communities to organize in real time, largely unfettered by borders. These applications include NFT marketplaces, play-to-earn games, decentralized autonomous organizations (DAOs), decentralized finance (DeFi) applications, and metaverse worlds.
As the leading self-custodial wallet, MetaMask acts as a digital authority manager for Web3 — only permitting websites and apps to access data that a user consents to. MetaMask’s in-app swap feature has enabled more than $10 billion USD in peer-to-peer token swapping. Additionally, MetaMask now supports Ethereum-compatible Layer 2 networks such as Polygon, Optimism, Arbitrum, zkSync, BSC, Celo, Avalanche, and NEAR/Aurora, which represents more than 90% of global smart contract network volume. An institution-compliant version of Metamask, MetaMask Institutional integrates custody and compliance solutions that enable organizations to access and engage in DeFi. ConsenSys is also ramping up its efforts to drive NFT adoption for artists, content creators, brands, rights owners, game publishers, and leagues.
ConsenSys’ developer tools and infrastructure are anchored by Infura, which is used by 350k developers , including MetaMask and leading DeFi and NFT platforms. Developers choose Infura because of its industry leading scale and performance, best-in-class documentation, and resources to help developers spend less time on infrastructure and more time building. ConsenSys is increasingly integrating its other products with Infura to support the entire development lifecycle, such as Truffle (4.7 million developers) for writing and testing smart contracts, Diligence for securing smart contracts with hands-on code audits and automated testing tools, and Customer Success for tech support. ConsenSys Quorum Blockchain Service offers a fully managed Ethereum blockchain service to enterprises. ConsenSys Quorum is already in use by 10 different Central Bank Digital Currency projects around the world. ConsenSys’ protocol and R&D engineers are main drivers of Ethereum’s upcoming merge which will bring the more energy efficient and scalable Proof of Stake consensus system to Ethereum.
Funding will support the rapid expansion of MetaMask and Infura’s industry leading products as well as the addition of 400 new roles across its products and services.
Joseph Lubin, Founder & CEO of ConsenSys and Co-creator of Ethereum said, “The Age of Silos and Trusted Third Parties (h/t @punk6529) is giving way to the Age of Community and Collaboration enabled by an automated, objective, trust foundation and a decentralized finance ecosystem. The paradigm shift to a world running on decentralized protocols is in full gear. The pace of adoption is now so rapid that we’ve more than doubled many of our core KPIs since this deal was struck over the summer. We are honored to partner with some of the top financial and strategic investors from both traditional and next generation economies to accelerate the realization of Web3. As our technology crosses into the mainstream, we are already seeing the transformation of how larger and larger cohorts of builders, users, artists, and enterprises live and work.”
Amit Rajpal, Partner and CEO Asia at Marshall Wace said, "We are excited to be investing in ConsenSys. The consumer, developer, and enterprise ecosystems for Defi and NFT applications are building exponentially and blockchain technology companies, like ConsenSys, which have multi-faceted technology offerings are in position to be the access point to this universe. We particularly look forward to working with Joe and his team to enhance their presence in the Asian region where adoption rates are rising rapidly."
Daniel S. Loeb, CEO and Founder of Third Point LLC said, “ConsenSys’ MetaMask wallet and other tools offer a unique platform for consumers, enterprises, and developers to engage, build, and create on the decentralized web. We are pleased to partner with ConsenSys to help unlock the unlimited potential of Web 3.0.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom